A new diagnostic method that ascertains if a person is suffering from Parkinson’s disease or dementia by looking at the manner of walking has been patented.
A new diagnostic technique developed by a St. Mary's Hospital research team in Uijeongbu has been patented and put up for patent registration, which analyses data from an individual's shoes to detect neurological disorders.
Most degenerative brain disorders, such as Parkinson's disease, dementia, and Lou Gehrig's disease, occur at an older age.
Currently, a costly MRI or a PET scan is required for such diagnosis, as well as frequent visits to the hospital.
The new approach, on the other hand, employs a "smart insole" that is placed inside a shoe and collects data from its sensors, which is then analyzed to assess the brain health of the wearer.
The new technique achieved an accuracy of 98.1 percent for the diagnosis of Parkinson's disease, as well as 83.2 percent for differentiating whether an illness is vascular or degenerative.


NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons 



